INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,671,351 | +98.6% | 791,335 | +18.5% | 0.02% | +87.5% |
| Q2 2023 | $7,387,848 | -3.5% | 667,979 | +17.2% | 0.01% | 0.0% |
| Q1 2023 | $7,655,436 | +198.9% | 570,025 | +175.3% | 0.01% | +166.7% |
| Q4 2022 | $2,561,605 | +526.3% | 207,082 | +605.8% | 0.00% | – |
| Q3 2022 | $409,000 | -84.7% | 29,342 | -82.1% | 0.00% | -100.0% |
| Q4 2021 | $2,666,000 | +17.6% | 163,634 | +7.2% | 0.00% | +50.0% |
| Q3 2021 | $2,267,000 | +176.1% | 152,651 | +271.4% | 0.00% | +100.0% |
| Q2 2021 | $821,000 | -53.3% | 41,100 | -46.0% | 0.00% | 0.0% |
| Q1 2021 | $1,757,000 | -52.2% | 76,094 | -48.8% | 0.00% | -66.7% |
| Q4 2020 | $3,672,000 | -54.6% | 148,669 | -23.8% | 0.00% | -66.7% |
| Q3 2020 | $8,084,000 | -1.0% | 194,987 | +14.4% | 0.01% | 0.0% |
| Q2 2020 | $8,163,000 | -37.2% | 170,400 | -17.5% | 0.01% | -55.0% |
| Q1 2020 | $12,998,000 | -33.4% | 206,435 | +31.1% | 0.02% | -9.1% |
| Q4 2019 | $19,508,000 | +204.3% | 157,428 | +63.0% | 0.02% | +175.0% |
| Q3 2019 | $6,410,000 | -5.7% | 96,600 | +13.1% | 0.01% | 0.0% |
| Q2 2019 | $6,795,000 | -42.1% | 85,400 | -18.6% | 0.01% | -46.7% |
| Q1 2019 | $11,735,000 | -58.5% | 104,903 | -62.6% | 0.02% | -62.5% |
| Q4 2018 | $28,285,000 | -11.7% | 280,640 | +10.7% | 0.04% | +2.6% |
| Q3 2018 | $32,039,000 | +554.3% | 253,555 | +334.5% | 0.04% | +457.1% |
| Q2 2018 | $4,897,000 | +218.4% | 58,352 | +133.4% | 0.01% | +250.0% |
| Q1 2018 | $1,538,000 | -44.6% | 25,000 | -47.4% | 0.00% | -50.0% |
| Q4 2017 | $2,777,000 | -56.8% | 47,532 | -57.1% | 0.00% | -60.0% |
| Q3 2017 | $6,433,000 | -42.9% | 110,832 | +19.0% | 0.01% | -44.4% |
| Q2 2017 | $11,276,000 | -0.9% | 93,141 | -7.4% | 0.02% | -10.0% |
| Q1 2017 | $11,378,000 | -59.4% | 100,607 | -61.0% | 0.02% | -57.4% |
| Q4 2016 | $28,033,000 | -2.7% | 258,007 | +47.3% | 0.05% | -7.8% |
| Q3 2016 | $28,820,000 | +19.2% | 175,104 | +3.4% | 0.05% | +15.9% |
| Q2 2016 | $24,171,000 | +8.1% | 169,404 | -2.7% | 0.04% | +10.0% |
| Q1 2016 | $22,366,000 | -15.5% | 174,093 | -1.8% | 0.04% | 0.0% |
| Q4 2015 | $26,465,000 | +27.3% | 177,200 | +41.4% | 0.04% | +29.0% |
| Q3 2015 | $20,783,000 | -25.8% | 125,300 | +8.0% | 0.03% | -26.2% |
| Q2 2015 | $27,993,000 | -9.7% | 115,975 | +5.5% | 0.04% | -10.6% |
| Q1 2015 | $31,013,000 | +479.6% | 109,970 | +220.6% | 0.05% | +571.4% |
| Q4 2014 | $5,351,000 | -14.8% | 34,300 | +29.3% | 0.01% | -12.5% |
| Q3 2014 | $6,279,000 | +155.1% | 26,526 | +155.1% | 0.01% | +166.7% |
| Q2 2014 | $2,461,000 | -86.4% | 10,400 | -81.1% | 0.00% | -88.5% |
| Q1 2014 | $18,159,000 | +3030.9% | 55,059 | +548.2% | 0.03% | +2500.0% |
| Q4 2013 | $580,000 | -65.9% | 8,494 | -65.5% | 0.00% | -66.7% |
| Q3 2013 | $1,702,000 | – | 24,653 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |